Recurrence Screening of Undifferentiated Pleomorphic Sarcoma with Giant Cells of the Breast
Clinical Laboratory · 2025
DOI: 10.7754/clin.lab.2025.250127 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Laboratory, 2025. Verfasst von Hua Fan und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Giant Cells, Sarcoma.
Abstract (Originalsprache)
BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) of the breast is a rare mesenchymal tumor that is not commonly encountered in clinical settings. Given its high recurrence rate, close monitoring, and follow-up are strongly recommended. METHODS: In this case, the recurrence of UPS with giant cells of the breast was screened through ultrasound imaging and tumor marker tests, including CA 15-3 and CA 72-4. RESULTS: Following recurrence, the patient achieved partial clinical remission after six cycles of epirubicin-based adjuvant chemotherapy. In accordance with the patient's preference, a left mastectomy was performed. Postoperatively, the patient's condition stabilized, with a smooth and satisfactory recovery. CONCLUSIONS: This case demonstrates that the combined evaluation of abnormal carbohydrate antigen expression and ultrasound features can enhance the diagnostic accuracy of suspected recurrent nodules following surgery for UPS of the breast.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Fan, H., & Qian, H. R. (2025). Recurrence Screening of Undifferentiated Pleomorphic Sarcoma with Giant Cells of the Breast. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2025.250127
Vancouver
Fan H, Qian HR. Recurrence Screening of Undifferentiated Pleomorphic Sarcoma with Giant Cells of the Breast. Clinical Laboratory. 2025. doi:10.7754/clin.lab.2025.250127
BibTeX
@article{Fan2025,
author = {Fan, Hua and Qian, Hong-Rong},
title = {Recurrence Screening of Undifferentiated Pleomorphic Sarcoma with Giant Cells of the Breast},
journal = {Clinical Laboratory},
year = {2025},
doi = {10.7754/clin.lab.2025.250127}
}
EUVIMED